Review On Reinventing Drug Safety Survillance in the Age of Digital Health

Ensuring the safety of medicines has long been a cornerstone of public health, traditionally relying on spontaneous reporting systems, clinical trials, and post-marketing surveillance to detect adverse drug reactions. While these methods have contributed significantly to patient safety, they are often limited by underreporting, delayed signal detection, and fragmented data sources (1). As healthcare systems grow increasingly complex and data-rich, these conventional pharmacovigilance approaches struggle to keep pace with the dynamic nature of real-world drug use (2). The rapid expansion of digital health technologies presents a transformative opportunity to reinvent drug safety surveillance. Electronic health records, wearable devices, mobile health applications, social media platforms, and real-world evidence databases are generating unprecedented volumes of longitudinal, patient-centric data. When combined with advances in artificial intelligence, machine learning, and big-data analytics, these digital tools enable earlier detection of safety signals, continuous monitoring across diverse populations, and more personalized risk assessment (3). Reinventing drug safety surveillance in the digital age requires a paradigm shift-from reactive, siloed systems to proactive, integrated, and learning health ecosystems. By harnessing digital health innovations while addressing challenges related to data quality, privacy, interoperability, and regulatory oversight, pharmacovigilance can evolve into a more responsive and predictive discipline. This evolution is essential not only for improving patient safety but also for strengthening public trust and supporting innovation in modern therapeutics (4). The purpose of this study is to examine how digital health technologies can transform drug safety surveillance by improving the detection, monitoring, and prevention of adverse drug events in real-world (5).

1.1 Concept of Drug Safety Surveillance

Drug safety surveillance, also known as pharmacovigilance, refers to the systematic process of detecting, assessing, understanding, and preventing adverse effects or any other drug-related problems throughout a medicine’s life cycle. While clinical trials establish a drug’s initial safety and efficacy, they are conducted in controlled environments with limited populations and durations. As a result, rare, long-term, or population-specific adverse drug reactions (ADRs) often emerge only after widespread use (7,8). Traditionally, drug safety surveillance has relied on spontaneous reporting systems, post-marketing studies, and regulatory monitoring. However, these methods are frequently limited by underreporting, delayed signal detection, and fragmented data sources. In the age of digital health, drug safety surveillance is evolving into a more continuous, data-driven, and real-time process, integrating electronic health records, mobile health technologies, wearable devices, social media data, and artificial intelligence to capture real-world drug safety information more effectively (9).

1.1.1 Importance of Drug Safety Surveillance

1. Protection of Patient Safety

The primary importance of drug safety surveillance lies in its role in protecting patients from preventable harm. By identifying adverse drug reactions early, surveillance systems help reduce morbidity, mortality, and avoidable healthcare costs associated with unsafe medication use.

2. Detection of Rare and Long-Term Adverse Effects

Many serious adverse effects are too rare or delayed to be detected during pre-marketing clinical trials. Drug safety surveillance enables the early identification of rare, chronic, or cumulative toxicities once drugs are used across diverse populations in real-world settings.

3. Support for Regulatory Decision-Making

Effective drug safety surveillance provides evidence for regulatory actions, including label updates, safety warnings, usage restrictions, or drug withdrawals. In the digital health era, enhanced data analytics support faster and more evidence-based regulatory responses.

4. Promotion of Rational and Safe Use of Medicines

Surveillance findings guide healthcare professionals in making informed prescribing decisions, improving benefit–risk assessment, and encouraging safer medication practices across healthcare systems.

5. Strengthening Public Trust in Healthcare Systems

Transparent and responsive drug safety surveillance systems help build public confidence in medicines, regulatory authorities, and healthcare providers. When safety issues are promptly identified and addressed, trust in medical innovation is reinforced.

6. Enabling Patient-Cantered Pharmacovigilance

Digital health tools empower patients to actively participate in drug safety surveillance through mobile reporting platforms and real-time symptom tracking, leading to more comprehensive and inclusive safety data.

7. Supporting Innovation in the Digital Health Era

As personalized medicine, biologics, and digital therapeutics expand, robust drug safety surveillance becomes essential for ensuring that innovation does not compromise safety. Advanced analytics and real-world evidence allow surveillance systems to keep pace with rapidly evolving therapies (10,11,12).

1.2 Limitations of conventional pharmacovigilance systems

1. Shift from Passive to Active Surveillance

• Use large real-world data networks.
• Continuous monitoring rather than waiting for reports.

2. Leverage Real-World Data (RWD)

• Electronic Health Records (EHRs)
• Pharmacy dispensing records
•  Use Artificial Intelligence & Advanced Analytics

• Natural Language Processing (NLP) for clinical notes
• Machine learning for signal detection
• Predictive modelling for risk stratification

4. Integrate Digital Health Technologies

• Wearables and remote monitoring devices
• Mobile health applications
• Social media signal mining

5. Improve Data Interoperability

• Standardized data models
• Cloud-based platforms
• Secure data-sharing frameworks

6. Patient-Centered Surveillance

• Direct patient reporting via digital apps
• Inclusion of patient-generated health data
• Transparency and feedback loops

7. Global Collaboration & Data Sharing

• Cross-border data networks
• Harmonized safety standards
• Public-private partnerships (13,14,15).

1.3 Emergence of digital health in drug safety surveillance

The emergence of digital health has significantly reshaped drug safety surveillance, offering faster, more dynamic ways to monitor adverse drug reactions (ADRs). Traditional pharmacovigilance systems relied heavily on spontaneous reporting, which often suffered from underreporting and delays. With the integration of digital technologies, real-time data collection and analysis have become increasingly feasible. Electronic health records (EHRs) provide a rich source of patient-level data, enabling continuous monitoring of drug safety across diverse populations. Mobile health applications and wearable devices further contribute by capturing real-world data on medication use, physiological parameters, and patient behaviour. These tools enhance early detection of potential safety signals (16). Social media platforms and online health forums are also being explored as unconventional data sources. They offer insights into patient experiences and can help identify emerging adverse effects that may not yet be formally reported. However, challenges such as data quality, noise, and privacy concerns must be addressed. Artificial intelligence (AI) and machine learning (ML) algorithms play a crucial role in processing large datasets, identifying patterns, and predicting potential risks. These technologies improve signal detection efficiency and reduce the burden on manual review processes. Natural language processing (NLP) further aids in extracting meaningful information from unstructured data. Digital health also supports patient-centric pharmacovigilance by encouraging direct patient reporting through user-friendly interfaces. This approach increases engagement and provides a more comprehensive understanding of drug safety in real-world settings. Despite these advancements, issues related to data standardization, interoperability, and regulatory acceptance remain significant barriers. Ensuring data security and maintaining patient confidentiality are critical considerations in digital surveillance systems. Overall, the integration of digital health into drug safety surveillance represents a transformative shift toward proactive, data-driven pharmacovigilance. It holds the potential to improve public health outcomes by enabling timely identification and mitigation of drug-related risks (17).

1.4 Traditional Approaches to Pharmacovigilance

1. Spontaneous Reporting Systems (SRS)

Also known as voluntary reporting systems, these are the cornerstone of traditional pharmacovigilance.

Examples:

• Uppsala Monitoring Centre (manages global ADR database)
• World Health Organization Programme for International Drug Monitoring
• Food and Drug Administration (FDA’s MedWatch program).

2. Case Reports and Case Series

• Individual case reports published in medical literature.
• Often the first signal of new or rare adverse reactions.
• Case series analyse patterns across multiple similar reports.

Example: Early detection of thalidomide-induced birth defects in the 1960s.

3. Cohort Studies

• Observational studies following a group exposed to a drug over time.
• Compare incidence of adverse events between exposed and non-exposed groups.

4. Case-Control Studies

• Compare patients with a specific adverse event (cases) to those without it (controls).
• Assess prior exposure to the suspected drug.

5. Clinical Trials (Pre-marketing Surveillance)

• Conducted before drug approval (Phase I–III).
• Assess safety and efficacy under controlled conditions.

6. Post-Marketing Surveillance (Phase IV Studies)

• Conducted after drug approval.
• Monitors real-world safety.
• May include observational studies or registries.

7. Prescription Event Monitoring (PEM)

• Active surveillance method.
• Tracks patients prescribed a specific medicine.
• Follow-up questionnaires sent to prescribers.

8. Drug Registries

• Organized systems collecting data on patients using specific medications.
• Often disease-based or drug-specific (18,19).

1.5 Digital Health Application in Drug Safety

1. Electronic Health Records (EHRs)

Electronic Health Records (EHRs) are digital, longitudinal records of a patient’s medical history, maintained by healthcare providers and accessible across authorized systems. They integrate clinical data such as diagnoses, medications, lab results, and treatment plans to support coordinated, efficient, and evidence-based care.

2. Mobile Health (mHealth) Apps

Mobile Health (mHealth) apps are software applications designed for smartphones and portable devices that support health monitoring, disease management, and wellness promotion. They enable users and healthcare providers to track, collect, and exchange health data in real time, facilitating more personalized and accessible care (20).

3. Wearable Devices & Remote Monitoring

Wearable devices and remote monitoring systems are sensor-based technologies that continuously capture physiological and behavioural data outside traditional clinical settings. They transmit real-time health information to users and healthcare providers, enabling proactive monitoring, early detection of abnormalities, and data-driven, personalized care.

4. Big Data & Data Mining

Big Data refers to extremely large, diverse, and rapidly generated datasets that exceed the capacity of traditional data-processing methods. Data mining involves applying computational and statistical techniques to these datasets to uncover hidden patterns, correlations, and actionable insights that support informed decision-making in healthcare and beyond.

5. Artificial Intelligence (AI) & Machine Learning

Artificial Intelligence (AI) refers to computer systems designed to perform tasks that typically require human intelligence, such as reasoning, perception, and decision-making. Machine Learning (ML), a subset of AI, enables these systems to learn from data patterns and improve their performance over time without explicit programming, supporting predictive and adaptive solutions in healthcare and other domains (21).

6. Social Media & Digital Surveillance

Social media refers to online platforms that facilitate the creation, sharing, and exchange of user-generated content, enabling real-time communication and information dissemination. Digital surveillance involves the systematic collection and analysis of digital interactions and behavioural data to monitor trends, support public health insights, and enhance decision-making in various sectors.

7. Clinical Decision Support Systems (CDSS)

Integrated into hospital systems, CDSS alerts healthcare providers about:

• Drug–drug interactions
• Contraindications
• Dose adjustments
• Allergy warnings

These systems reduce medication errors and prevent adverse events before they occur.

8. Telemedicine

Remote consultations allow monitoring of patients on high-risk medications.

Example:

Monitoring adverse reactions in oncology, psychiatry, and chronic disease therapy (22).

Fig.1 Traditional Approaches to Pharmacovigilance